$GILD

Mercier Johanna sold $372K of GILD

Mercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares of GILEAD SCIENCES, INC. (GILD) at an average of $123.92 ($123.42–$125.40, $0.37M total) across 3 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mercier Johanna
Published Jun 16, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GILD
Neutral
high confidence
Mentioned
$GILD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale of 3,000 shares on 2026-06-15 at ~$123.92 weighted average, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment/positioning, but it is unlikely to drive fundamentals absent corroborating news.

03

What to watch

The article provides only the sale details; it does not indicate whether other insiders or large holders changed positions around the same period.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-16; sale executed 2026-06-15.

Background

This is an SEC Form 4 insider transaction disclosure for Gilead Sciences, reported via SEC EDGAR.

Company-level read

Ticker impact

$GILDNeutralHigh confidence
Context

Gilead’s chief comm & corporate affairs officer sold about 3,000 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low near-term impact; any effect is likely sentiment-only and should fade unless accompanied by other news.

Evidence & confidence

The filing is a Form 4 insider sale with explicit 10b5-1 pre-arrangement, which generally reduces interpretive weight versus discretionary selling.

Market effects

Minimal—single-company insider transaction without any operational/regulatory/clinical catalyst.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal expectations of near-term volatility or liquidity needs; traders may still watch for clustering of sales.

Key entities

  • Gilead Sciences, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Mercier Johanna

    Chief Comm & Corp Aff Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as Yes, reducing discretionary-signal strength.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GILDMed

5 Breast Cancer Advances in 2026—And The Questions They Leave Unanswered

The FDA approved several breast cancer treatments in 2026, including Daiichi Sankyo's fam-trastuzumab deruxtecan for early-stage HER2-positive breast cancer, datopotamab deruxtecan for triple-negative breast cancer, Gilead Sciences' sacituzumab govitecan for first-line TNBC, Pfizer's palbociclib for maintenance therapy, and AstraZeneca's camizestrant for HR-positive, HER2-negative advanced breast cancer.

$GILDHighAI 9/10

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.

$VIRHighAI 9/10

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal

Vir Biotechnology and Gilead Sciences agreed to collaborate on cancer therapies for solid tumors, with a deal potentially worth up to $1.88 billion. Vir will receive $90 million upfront and could earn additional milestone payments and royalties. The partnership focuses on developing three drug candidates using Vir's technologies. Vir shares rose over 10% in premarket trading.

$VIRHighAI 8/10

Vir Biotechnology partners with Gilead on cancer therapies

Vir Biotechnology (VIR) and Gilead Sciences (GILD) announced a collaboration to develop cancer therapies. VIR will receive $90M upfront, with potential milestones up to $1.74B. VIR will handle discovery, while GILD will develop and commercialize the therapies. The deal focuses on T-cell engagers targeting solid tumors.